Back to Agenda
Session 6BC: What, Where, and How: Biomarkers Inform Disease Targets, Biodistribution, and Function of Oligonucleotide Therapeutics
Session Chair(s)
Aimee L. Jackson, PHD
, Miragen Therapeutics, United States
This session will present preclinical and clinical data on the identification and validation of biomarkers for oligonucleotide therapeutics. Discussions will include methods to identify pharmacodynamic biomarkers, use of biomarkers to define PK/PD and dose-response relationships, the application of biomarkers to establish mechanistic proof-of-concept and guide dose optimization, and how biomarkers can inform disease status and patient enrichment.
Learning Objective :
Speaker(s)
Imran Khan, PHD
Pharmacologist, OMPT, OND, ODEI, DPP, CDER, FDA, United States
Session Co-Chair
Aimee L. Jackson, PHD
, Miragen Therapeutics, United States
Translating PD Biomarkers from Preclinical Studies to Clinical Trials: MRG-106, an Oligonucleotide Inhibitor of miR-155, Coordinately Regulates Multiple Survival Pathways to Reduce Cellular Proliferation, and Survival in Cutaneous T-Cell Lymphoma
Corrie L Gallant-Behm, PHD
Research Scientist III, Miragen Therapeutics, Inc., United States
Translating PD Biomarkers from Preclinical Studies to Clinical Trials: MRG-201, an Oligonucleotide Mimic of miR-29, Inhibits Collagen Expression, and Reduces Fibroplasia in Cutaneous Wounds
William Querbes, PHD
Director, Research, Alnylam Pharmaceuticals, United States
Use of Biomarkers in the Development of RNAi Therapeutics
Panel Discussion
, All Session Speakers, United States
Have an account?